Page 49 Opióides

30. Citron ML, Johnson-Early A, Boyer M, et al. Patient-controlled analgesia for severe cancer pain. Arch
Intern Med 1986;146:734-6.
31. Ferrell BR, Nash CC, Warfield C. The role of patient-controlled analgesia in the management of
cancer pain. J Pain Symptom Manage 1992;7:149-54.
32. Swanson G, Smith J, Bulich R, et al. Patient controlled analgesia for chronic cancer pain in the am-
bulatory setting: A report of 117 patients. J Clin Oncol 1989;7:1903-8.
33. Ferrante FM, Ostheimer GW, Covino BG, editors. Patient-controlled analgesia. Boston: Blackwell
Scientific Publications 1990.
34. Storey P, Hill HH Jr, St Louis RH, et al. Subcutaneous infusions for control of cancer symptoms.
J Pain Symptom Manage 1990;5:33-40.
35. Aliaga L, Hansen E. Perfusión continua subcutânea en el dolor crónico. Dolor 1991;Suppl 3:75-7.
36. Moulin DE, Kreeft JH, Murray-Parsons N. Comparison of continuous subcutaneous and intravenous
hydromorphone infusion for management of cancer pain. Lancet 1991;337:465-8.
37. Brown JG. Systemic Opioid Analgesia for Postoperative Pain Management. Anesth Clin of North Am
1989;7(1):51-62.
38. Bruera E, Brenneis C, MacDonald RN. Continuous Sc infusion of narcotics for the treatment of
cancer pain: an update. Cancer Treat Rep 1987;71:953-8.
39. Covle N, Mauskop A, Maggard J, et al. Continuous subcutaneous infusions of opiates in cancer patients
with pain. Oncol Nuts Forum 1986;13:53-7.
40. Bruera E, Brenneis C, Michaud M, et al. Patient-controlled subcutaneous hydromorphone versus
continuous subcutaneous infusion for the treatment of cancer pain. J Natl Cancer Inst
1988;80:1152-4.
41. Bruera E, Macmillan K, Selmser P, MacDonald RN. Decreased local toxicity with subcutaneous dia-
morphine (heroin): a preliminary report. Pain 1990;43:91-4.
42. Waldmann CS, Eason JR, Rambohul E, et al. Serum morphine levels: a comparison between continu-
ous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthe-
sia 1984;39:768-71.
43. Moulin DE, Johnson NG, et al. Subcutaneous narcotic infusions for cancer pain: Treatment outcome
and guidelines for use. Can Med Assoc J 1992;146(6):891-7.
44. Austin KL, Stapleton JV, Mather LE. Multiple intramuscular injections: a major source of variability
in analgesic response to meperidine. Pain 1980;8:47-51.
45. Kaiko RF, Methadone plasma levels and analgesia in postoperative cancer patients. Em: Walker CA,
Tterlikkis LP (eds). Application of pharmacokinetics to patient care. Nova Iorque: Praeger Scientific:
119-34.
46. Schwartz ML, Meyer MB, Covino BG, et al. Antiarrythmic effectiveness of intermuscular lidocaine:
influence of different injection sites. J Clin Pharmacol 1974;14:77-83.
47. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered
fentanyl. Anesthesiology 1998;70:928-34.
48. Lehmann KA, Zech D. Transdermal fentanyl, clinical pharmacology. J Pain Symptom Manage
1992;7:8-16.
49. Calis KA, Kohler DR, Corso DM. Transdermally administered fentanyl for pain management. Clin
Pharm 1992;11:22-36.
50. Donner B, Zenz M, Tryba M, et al. Fentanyl-TTS for postoperative pain therapy. A new alternative?
Anaesthetist 1993;42(5):309-15.
51. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose
pharmacokinetics. Anesthesiology 1993;78(1):36-43.
52. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;
41(3):273-81.
53. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics.
Clin Pharmacol Ther 1998;44:335-42.
54. Henderson JM, Brodsky DA, Fisher DM, et al. Pré-induction of anaesthesia inpediatric patients with
nasally administered sufentanil. Anesthesiology 1988;68:671-5.
55. Vercauteren M, Boeckx E, Hanegreefs G, et al. Intranasal sufentanil for pré-operative sedation. An-
aesthesia 1988;43:270-3.
56. Helmers JH, Noorduin H, Van Peer A, et al. Comparasion of intravenous and intranasal sufentanil
absorption and sedation. Can J Anaesth 1989;36:494-7.
57. Gaynes G, Brahen NH, Hill HF. Plasma sufentanil concentration after intranasal administration to
paediatric outpatients. Can J Anaesth 1993;40:286-8.
58. Stirbel HW, Pommerening J, Rieger A. Intranasal fentanyl titration for postoperative pain management
in an unselected population. Anaesthesia 1993;48:753-7.
59. Striebel HW, Koenings D, Kraer J. Postoperative pain management by intranasal demandadapted
fentanyl titration. Anaesthesiology 1992;77:281-5.

46